Use the hyperlinks, where available to access additional clinical trial information.
A phase II, open-label, randomised, controlled trial of Ipilimumab and Nivolumab with concurrent intracranial stereotactic radiotherapy versus Ipilimumab and Nivolumab alone in patients with melanoma brain metastases
Bristol-Myers Squibb (BMS)
Other Non-Commercial Sponsor
Melanoma Institute Australia
All eligible patients will receive Nivolumab and Ipilimumab every three weeks for four cycles, then Nivolumab every 4 weeks. Some patients will receive either a single or multiple sessions of stereotactic radiotherapy, within the first 5 days of the targeted therapy. Salvage therapy may be administered to any patient if the disease progresses.